The American Food and Barments Administration ( The FDA has asked producers of Ozempic, Wegovy and other drugs for diabetes and weight loss to add a new warning to security information.
Warning is linked to the danger of a rare damage to optic nerve, which can cause sudden loss of vision in one eye. In some cases, damage can be permanent.
The request, released on November 9th, includes Mounjaro and Zepboard drugs, which belong to the GLP-1 drug group.
The situation in question is known as NAION and caused by the reduction of the blood supply of a piece of optic nerve. It can appear suddenly and painless, causing weakness of sight.
What do the data indicate?
According to the FDA analysis, which included 126 clinical trials with more than 134 thousand participants, 6.4 cases of this situation have been observed for every 100,000 person-year in patients who used GLP-1 drugs.
In the group that took placebo or other blood sugar reduction drugs, the rate was 3.8 cases for 100,000 people-years. In general, the analysis identified 15 possible cases.
Meanwhile, the European Barnets Agency ( EMA had classified it since June 2025 NATION as the very rare side effect of semaglutis, the active components of Ozempic, Wegovy and Rybelsus.
According to EMA’s assessment, this situation can affect as many as one in 10,000 people using semaglutid.
The FDA has called on patients using these drugs to contact a health professional immediately if they observe sudden weakening of vision, dark areas in the visual field, or other changes of vision in one eye.
Source Layer: Insander